
People with a deadly form of skin cancer could live longer with an innovative one-time treatment that harnesses a patient’s own immune system to fight the disease, researchers have suggested.
Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking in the majority of cases, a trial has found.